Brief: Geneuro FY Operating Loss Widens To 8.1 Million Euros

Geneuro SA

01/04/2019 06:43

April 1 (Reuters) - GENEURO SA  GNRO.PA :
    * FULL 12-MONTH RESULTS FROM PHASE 2A STUDY IN TYPE 1
DIABETES ARE
EXPECTED IN Q2 2019 
    * GENEURO REPORTS 2018 FULL-YEAR RESULTS AND PROVIDES
CORPORATE
UPDATE
    * SOLID CASH POSITION OF EUR 16.5 MILLION, INCLUDING CREDIT
FACILITY OF EUR 7.5 MILLION
    * SUCCESSFUL ANGEL-MS PHASE 2B EXTENSION STUDY RESULTS
CONFIRM AND
EXTEND NEUROPROTECTIVE EFFECTS OF TEMELIMAB IN MS
    * FINAL 12-MONTH RESULTS FROM PHASE 2A TYPE 1 DIABETES TRIAL
EXPECTED Q2 2019
    * GENEURO IS MAKING SIGNIFICANT CLINICAL PROGRESS IN 2019
AND HAS
A SOLID FINANCIAL VISIBILITY UNTIL MID-2020 - CEO
    * CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 9.0 MILLION AT
DECEMBER 31, 2018, COMPARED TO EUR 26.6 MILLION AT DECEMBER 31,
2017
    * GENEURO'S PRIORITIES FOR 2019 REMAIN DEVELOPMENT OF ITS
CLINICAL
AND SCIENTIFIC RESEARCH PROGRAMS
    * FY OPERATING LOSS EUR 8.1 MILLION VERSUS EUR 5.7 MILLION
YEAR
AGO
    * CONTINUE PRE-CLINICAL PROGRAM IN AMYOTROPHIC LATERAL
SCLEROSIS
WITH OBJECTIVE TO OBTAIN AN IND BY MID-2020
    * FY NET LOSS FOR THE PERIOD 8.3 MILLION VERSUS EUR 5.8
MILLION
YEAR AGO
    * FY INCOME EUR 7.5 MILLION VERSUS EUR 14.9 MILLION YEAR AGO

Source text for Eikon:  ID:nBw6VwFJsa 
Further company coverage:  GNRO.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))